Zhang Zhihui, Yang Liu, Li Yujiang, Wu Yunfei, Li Xiang, Wu Xu
Department of Thoracic and Cardiovascular Surgery/Huiqiao Medical Center, Nanfang Hospital, Southern Medical University, Jingxi Street, Guangzhou, Guangdong 510515, China.
Department of Radiology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Open Med (Wars). 2021 Apr 21;16(1):660-671. doi: 10.1515/med-2021-0276. eCollection 2021.
Lung adenocarcinoma (LUAD) is currently one of the most common malignant tumors worldwide. However, there is a lack of long noncoding RNA (lncRNA)-based effective markers for predicting the prognosis of LUAD patients. We identified four lncRNAs that can effectively predict the prognosis of LUAD patients.
We used data gene expression profile for 446 patients from The Cancer Genome Atlas database. The patients were randomly divided into a training set and a test set. Significant lncRNAs were identified by univariate regression. Then, multivariate regression was used to identify lncRNAs significantly associated with the survival rate. We constructed four-lncRNA risk formulas for LUAD patients and divided patients into high-risk and low-risk groups. Identified lncRNAs subsequently verified in the test set, and the clinical independence of the lncRNA model was evaluated by stratified analysis. Then mutated genes were identified in the high-risk and low-risk groups. Enrichment analysis was used to determine the relationships between lncRNAs and co-expressed genes. Finally, the accuracy of the model was verified using external database.
A four-lncRNA signature (AC018629.1, AC122134.1, AC119424.1, and AL138789.1) has been verified in the training and test sets to be significantly associated with the overall survival of LUAD patients.
The present study demonstrated that identified four-lncRNA signature can be used as an independent prognostic biomarker for the prediction of survival of LUAD patients.
肺腺癌（LUAD）是目前全球最常见的恶性肿瘤之一。然而，缺乏基于长链非编码RNA（lncRNA）的有效标志物来预测LUAD患者的预后。我们鉴定出了四种能够有效预测LUAD患者预后的lncRNA。
我们使用了来自癌症基因组图谱数据库的446例患者的数据基因表达谱。将患者随机分为训练集和测试集。通过单变量回归鉴定出显著的lncRNA。然后，使用多变量回归来鉴定与生存率显著相关的lncRNA。我们构建了LUAD患者的四lncRNA风险公式，并将患者分为高风险组和低风险组。随后在测试集中验证鉴定出的lncRNA，并通过分层分析评估lncRNA模型的临床独立性。然后在高风险组和低风险组中鉴定突变基因。使用富集分析来确定lncRNA与共表达基因之间的关系。最后，使用外部数据库验证模型的准确性。
一种四lncRNA特征（AC018629.1、AC122134.1、AC119424.1和AL138789.1）已在训练集和测试集中得到验证，与LUAD患者的总生存期显著相关。
本研究表明，鉴定出的四lncRNA特征可作为预测LUAD患者生存的独立预后生物标志物。
